Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model

Urology

Volumn 80, Issue 3, 2012, Pages 736.e1-736.e5

  Chan, Eddie Shu Yin ^a   Patel, Amit R ^b   Hansel, Donna E ^c   Larchian, William A ^d   Heston, Warren D ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; KI 67 ANTIGEN; PLACEBO; SODIUM CHLORIDE; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTRAST ENHANCEMENT; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HYDROURETER; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; TUMOR GROWTH; ULTRASOUND;

EID: 84865500126     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.04.038     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J.P. Stein, G. Lieskovsky, R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
3. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 202 205
4. D.J. Hicklin, L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1011 1027
5. G. Xia, S.R. Kumar, D. Hawes Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J Urol 175 2006 1245 1252
6. J.P. Crew, T. O'Brien, M. Bradburn Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer Cancer Res 57 1997 5281 5285
7. C.C. Yang, K.C. Chu, W.M. Yeh The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression Urol Oncol 22 2004 1 6
8. S. Bernardini, S. Fauconnet, E. Chabannes Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer J Urol 166 2001 1275 1279
9. E.S. Chan, A.R. Patel, A.K. Smith Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model J Urol 182 2009 2926 2931
10. A.R. Patel, E.S. Chan, D.E. Hansel Transabdominal micro-ultrasound imaging of bladder cancer in a mouse model: a validation study Urology 75 2010 799 804
11. N. Weidner, J.P. Semple, W.R. Welch Tumor angiogenesis and metastasiscorrelation in invasive breast carcinoma N Engl J Med 324 1991 1 8
12. B.H. Bochner, R.J. Cote, N. Weidner Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis J Natl Cancer Inst 87 1995 1603 1612
13. E.S. Chan, A.R. Patel, W.A. Larchian Initial application of in vivo targeted contrast-enhanced micro-ultrasound imaging for measuring intra-tumoral perfusion and vascular endothelial growth factor receptor 2 expression in a mouse orthotopic bladder cancer model J Urol 185 2011 2359 2365
14. E.H. Streeter, J.P. Crew Angiogenesis, angiogenic factor expression and prognosis of bladder cancer Anticancer Res 21 2001 4355 4363
15. R.J. Motzer, T.E. Hutson, P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
16. P. Kupsch, B.F. Henning, K. Passarge Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer Clin Colorectal Cancer 5 2005 188 196
17. C.A. Carter, C. Chen, C. Brink Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma Cancer Chemother Pharmacol 59 2007 183 195
18. R. Nakanishi, N. Oka, H. Nakatsuji Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer Urol Int 83 2009 98 106
19. A.M. O'Farrell, T.J. Abrams, H.A. Yuen SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 2003 3597 3605
20. G. Sonpavde, W. Jian, H. Liu Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model Urol Oncol 27 2009 391 399
21. D.M. Chapman, K.S. Pohar, M.C. Gong Preoperative hydronephrosis as an indicator of survival after radical cystectomy Urol Oncol 27 2009 491 495
22. J.C. Goddard, C.D. Sutton, P.N. Furness Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer Clin Cancer Res 9 2003 2583 2586
23. T. Asakura, Y. Takano, M. Iki Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer J Urol 158 1997 385 388
24. A. Broillet, J. Hantson, C. Ruegg Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies Acad Radiol 12 suppl 1 2005 S28 S33
25. J.P. O'Connor, R.A. Carano, A.R. Clamp Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Clin Cancer Res 15 2009 6674 6682
26. J.K. Willmann, R. Paulmurugan, K. Chen US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice Radiology 246 2008 508 518
27. A. Lyshchik, A.C. Fleischer, J. Huamani Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography J Ultrasound Med 26 2007 1575 1586
28. D.B. Mendel, A.D. Laird, X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337
29. A. Takeuchi, M. Eto, M. Shiota Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation Int J Oncol 40 2012 1691 1696
30. C.Y. Yoon, J.S. Lee, B.S. Kim Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells Korean J Urol 52 2011 55 63